Diabetes Mellitus, Obesity and Metabolic Dysregulation as Risk Factors for Metabolic Associated Fatty Liver Disease (MAFLD)

Background and Aim: The new nomenclature of metabolic syndrome (MeS) associated fatty liver disease (MAFLD) is characterized by hepatic steatosis (FL) the presence at least one following i.e. Type 2 diabetes mellitus, obesity dysregulation. aim this study was to determine risk factor profile individual components MAFLD. Methods: From October December 2022, 341 patients coming in for master health check-ups centers were screened FL, assessed 3 conditions: Diabetes Mellitus (T2DM), overweight/obesity (BMI 23 kg/m2) dysregulation (APASL criteria: 5 criteria) WC 90 (men); 80 cm (women); BP >130/85 mm Hg, TGL >150 mg/dL, HDL <40 mg/dL <50 (women), prediabetes (B sugar (fasting) 100-125 or postprandial 140-199 HbA1c 5.7-6.4%. Patients evaluated these conditions FL. Results: Of 190 with 172 had dysfunction (90.5%), 164 raised BMI (86.3%) 69 (36.3%). A combination MeS high present 97 (51.1%) all three 52 (27.4%). (12.1%) found have Lean type MAFLD i.e < kg/m2. In absence FL (151 patients), 104 (54.7%) MeS, 34 (22.5%) T2DM 91 (60.3%) BMI. Significant contributors were: Overweight/obese (Odds Ratio (OR) 4.16) Waist circumference (men) (OR 5.61), mellitus 1.96) Raised Triglyceride levels 4.77). Conclusion: Diagnosis based on definite indicators can help enhance identification at-risk patient groups tailor management.